Precision ADVANCE Overview
Precision ADVANCE Clinical Services Overview
Precision ADVANCE Commercial Services Overview
Precision ADVANCE Manufacturing Services Overview
Building the first-of-its kind gene therapy facility, commercializing one of the first gene therapies and industrializing the largest gene therapy footprint in the world
Navigating the CAR T-cell Therapy Landscape to Develop Market Access and Distribution Strategies
Process and Communication: Navigating Logistical Complexity in Matched Cellular Therapy Trials
Mining Stakeholder Insights on Access to Gene Therapies for Hemophilia
The Value of Gene Therapy in Spinal Muscular Atrophy
Ensuring Provider Education And Readiness For Using A Novel CAR-T
Delivering on the Promise of Cell Therapy: Challenges and Trends
Optimizing Successful Development of Viral Vector Gene Therapies, Gene Therapy Trials, and Companion Diagnostics
Perspectives on Gene Therapy: Defining and Demonstrating Value to Payers
Advantages of Using POD Cleanroom Technology
What to Consider When Conducting a “Make vs. Buy” Analysis for a Cell & Gene Therapy Facility
Developing Advanced Therapies: Considerations for Internal vs External Manufacturing
2021 Gene Therapy for Rare Disorders Panel
Endpoints Webinar: The Great Debate: Internal vs External Manufacturing for Advanced Therapies
BioProcess Interview: Tackling the Cell & Gene Manufacturing Talent Crunch
Economic assessment of novel gene and cellular therapies: beyond traditional modeling. J Clin Pathways. 2018; 5:35-36.
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Journal of Market Access & Health Policy. 2019; VOL. 7, 1-13.
Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS Study. ISPOR 25th Annual International Meeting. Orlando FL. 2020.
Healthcare resource use and expenditures in patients with X-linked myotubular myopathy (XLMTM). ISPOR 25th Annual International Meeting. Orlando FL. 2020.
Economic Burden of X-Linked Myotubular Myopathy (XLMTM) By Ventilation Status. ISPOR 25th Annual International Meeting. Orlando FL. 2020.
Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays
Immunogenicity of Chimeric Antigen Receptor T‑Cell Therapeutics
Perspective on Gene Therapy: Defining and Demonstrating Value to Payers